AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
MILAN, Sept. 05, 2025 (Korea Bizwire) – AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated clinical data from the LUCE-1 study at the 25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025), taking place in Paris 4-7 September 2025. Data presented by Prof. [...]










